Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05126199
Other study ID # TimeMAP
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 5, 2021
Est. completion date January 31, 2023

Study information

Verified date September 2022
Source Tallaght University Hospital
Contact Ruairí Floyd, BSc BMBS
Phone (01) 414 2000
Email floydr@tcd.ie
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Polycystic ovarian syndrome (PCOS) is associated with metabolic symptoms such as hyperinsulinemia. Time-restricted eating may reduce serum insulin and improve insulin resistance in patients with PCOS. Currently, there are few studies investigating time-restricted eating in patients with PCOS. The investigators plan to test the feasibility of time-restricted eating in the management of PCOS by means of a real-world clinical intervention. The investigators will determine if an 18:6 eating protocol reduces insulin levels by means of a randomised controlled crossover trial.


Description:

Background: Polycystic ovarian syndrome (PCOS) is the most common reproductive endocrinopathy in women of reproductive age with many associated metabolic symptoms, in particular hyperinsulinemia, insulin resistance and a high lifetime risk of type 2 diabetes mellitus. The effects of time-restricted eating on metabolic profiles have been investigated in many endocrinopathies, but there are minimal data in PCOS. Methods: This study will investigate the feasibility of time-restricted eating in the management of PCOS, and its effects on insulin levels and other metabolic parameters. To achieve this, the investigators will recruit 20 patients with PCOS (normal weight, overweight, obese). In a randomised cross-over design, participants will be observed for two consecutive 12 week periods (with a 4 weeks washout period in between) following either 'time-restricted eating' or 'usual eating', detailed below. 1. 18:6 protocol: 18 hours of fasting and a 6-hours eating window, with no other specific dietary advice. Participants choose their own 6-hour period according to their lifestyle and preference. 2. Usual eating: follow usual eating patterns, no time restriction, no other dietary advice When fasting, participants are permitted to consume plain water, unflavoured/unsweetened sparkling water, black breakfast tea and black coffee. Dietary intake will be determined at baseline, at midpoint of each study arm, and at the end of the study using Nutritics software. Participants will self-record dietary intake using the Nutritics 'app'. The primary endpoints will be serum insulin and feasibility of the intervention as well as safety, acceptability, and compliance with time-restricted eating. Secondary endpoints will be insulin resistance (Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)), androgens (testosterone, free testosterone, dehydroepiandrosterone sulfate (DHEA-S), androstenedione, 17-Hydroxyprogesterone (17-OHP) and sex hormone binding globulin (SHBG)), appetite (10-point visual analogue scale), hunger/satiety (glucagon-like peptide 1 (GLP-1), grehlin, PYY and oxyntomodulin, fasting glucose, HbA1c, lipid profile, lipoprotein lipid A, apolipoprotein A1, apolipoprotein B, anthropometrics (weight, body mass index, hip and waist circumference), dietary intake (calorie and macronutrient intake; micronutrient intake including iron, calcium; dietary pattern including timing). Results: Safety and acceptability will be measured by adverse event reporting and measurement of adherence. Paired t-test will be used to assess between baseline and post intervention measurements. Results considered statistically significant if p<0.05. Discussion: Time-restricted eating has potential to aid in improvement of insulin resistance in patients with PCOS based on studies in other populations. There is no substantial literature on this subject to date in the PCOS patient cohort, with this being the first randomised study to date. The investigators will discuss the effects of time-restricted eating on insulin levels in the specific population of women with PCOS based on the results.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date January 31, 2023
Est. primary completion date December 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 42 Years
Eligibility Inclusion Criteria: - Adult women of reproductive age with confirmed diagnosis of PCOS (Rotterdam Criteria, including at least 2 of 3 characteristics: oligomenorrhea, clinical and/or biochemical hyperandrogenism and ultrasound criteria) - No BMI restriction - Able and willing to provide explicit, informed consent Exclusion Criteria: - Type 1 diabetes, medication-controlled type 2 diabetes - Pregnancy - Currently participating in weight loss programme, or reported weight change in last 3 months (>5% of current body weight) - Documented history of eating disorder - Ovulation medication, such as clomiphene citrate - Weight loss medication affecting weight or appetite in last 6 months, including weight loss medications, antipsychotic drugs or other medications as determine by the physician (eg. Semaglutide, liraglutide, orlistat, amphetamines, Qsymia (phentermine-topiramate), bupropion-naltrexone (Contrave)) - Known liver, renal or thyroid dysfunction (not including non-alcoholic fatty liver disease with hypothyroidism on treatment or subclinical hypothyroidism seen in a large proportion of patients with PCOS) - Unable to participate in follow-up for at least 24 weeks - Unable or unwilling to provide explicit, informed consent

Study Design


Intervention

Other:
Time restricted eating
Following a 3 day baseline dietary assessment using the Nutritics 'app', patients will immediately commence time-restricted eating on a 18:6 basis (18 hours fasting, 6 hours eating window) for 12 weeks. Participants will consume all their meals within a daily 6-hour period of their choosing, and this may change according to patient's lifestyle and preference to reflect a real-world situation. Participants may eat ad libitum / according to appetite during the eating period. Participants will fast for 18 hours per day, consuming only plain water, unflavoured/unsweetened sparkling water, black breakfast tea or black coffee. Alcohol must not be consumed during fasting periods Dietary intake will again be measured using the Nutritics 'app' midpoint through the 12-week period (week 6 +/- 1 week) and in the last week of the intervention (week 11/12).
Normal ad libitum diet
Following a 3-day baseline dietary assessment using the Nutritics 'app', participants with be directed to continue with their usual dietary intake without any time-related restrictions for 12 weeks. There will be no defined eating window and fasting or restrictions regarding types of food or drink consumed. Dietary intake will again be measured using the Nutritics 'app' midpoint through the 12-week period (week 6 +/- 1 week) and in the last week of the intervention (week 11/12).

Locations

Country Name City State
Ireland Robert Graves Institute of Endocrinology, Tallaght University Hospital Dublin Leinster

Sponsors (2)

Lead Sponsor Collaborator
Ruairí Floyd Tallaght University Hospital

Country where clinical trial is conducted

Ireland, 

References & Publications (8)

Albosta M, Bakke J. Intermittent fasting: is there a role in the treatment of diabetes? A review of the literature and guide for primary care physicians. Clin Diabetes Endocrinol. 2021 Feb 3;7(1):3. doi: 10.1186/s40842-020-00116-1. Review. — View Citation

Anton SD, Moehl K, Donahoo WT, Marosi K, Lee SA, Mainous AG 3rd, Leeuwenburgh C, Mattson MP. Flipping the Metabolic Switch: Understanding and Applying the Health Benefits of Fasting. Obesity (Silver Spring). 2018 Feb;26(2):254-268. doi: 10.1002/oby.22065. Epub 2017 Oct 31. Review. — View Citation

Asemi Z, Samimi M, Taghizadeh M, Esmaillzadeh A. Effects of Ramadan Fasting on Glucose Homeostasis, Lipid Profiles, Inflammation and Oxidative Stress in Women with Polycystic Ovary Syndrome in Kashan, Iran. Arch Iran Med. 2015 Dec;18(12):806-10. doi: 0151812/AIM.003. — View Citation

de Cabo R, Mattson MP. Effects of Intermittent Fasting on Health, Aging, and Disease. N Engl J Med. 2019 Dec 26;381(26):2541-2551. doi: 10.1056/NEJMra1905136. Review. Erratum in: N Engl J Med. 2020 Jan 16;382(3):298. N Engl J Med. 2020 Mar 5;382(10):978. — View Citation

Li C, Xing C, Zhang J, Zhao H, Shi W, He B. Eight-hour time-restricted feeding improves endocrine and metabolic profiles in women with anovulatory polycystic ovary syndrome. J Transl Med. 2021 Apr 13;19(1):148. doi: 10.1186/s12967-021-02817-2. — View Citation

Pellegrini M, Cioffi I, Evangelista A, Ponzo V, Goitre I, Ciccone G, Ghigo E, Bo S. Effects of time-restricted feeding on body weight and metabolism. A systematic review and meta-analysis. Rev Endocr Metab Disord. 2020 Mar;21(1):17-33. doi: 10.1007/s11154-019-09524-w. Erratum in: Rev Endocr Metab Disord. 2020 Feb 18;:. — View Citation

Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018 Aug;110(3):364-379. doi: 10.1016/j.fertnstert.2018.05.004. Epub 2018 Jul 19. Review. — View Citation

Zangeneh F, Salman Yazdi R, Naghizadeh MM, Abedinia N. Effect of Ramadan Fasting on Stress Neurohormones in Women with Polycystic Ovary Syndrome. J Family Reprod Health. 2015 Jun;9(2):51-7. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Drop-out rate Assessing intervention feasibility 6 weeks
Primary Drop-out rate Assessing intervention feasibility 12 weeks
Primary Adverse outcomes as assessed by CTCAE v4.0 Assessing intervention feasibility 6 weeks
Primary Adverse outcomes as assessed by CTCAE v4.0 Assessing intervention feasibility 12 weeks
Primary Change in serum insulin Measured with serum insulin levels to assess effects 6 weeks
Primary Change in serum insulin Measured with serum insulin levels to assess effects 12 weeks
Primary Change in food diaries Assessment of change of eating behaviours 6 weeks
Primary Change in food diaries Assessment of change of eating behaviours 12 weeks
Secondary Change in insulin resistance Assessed by Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) and other ratio calculations measuring insulin resistance 6 weeks
Secondary Change in insulin resistance Assessed by Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) and other ratio calculations measuring insulin resistance 12 weeks
Secondary Change in testosterone levels Assessed by plasma testosterone 6 weeks
Secondary Change in testosterone levels Assessed by plasma testosterone 12 weeks
Secondary Change in free testosterone levels Assessed by plasma free testosterone 6 weeks
Secondary Change in free testosterone levels Assessed by plasma free testosterone 12 weeks
Secondary Change in dehydroepiandrosterone sulfate (DHEA-S) levels Assessed by plasma dehydroepiandrosterone sulfate (DHEA-S) 6 weeks
Secondary Change in dehydroepiandrosterone sulfate (DHEA-S) levels Assessed by plasma dehydroepiandrosterone sulfate (DHEA-S) 12 weeks
Secondary Change in androstenedione levels Assessed by plasma androstenedione 6 weeks
Secondary Change in androstenedione levels Assessed by plasma androstenedione 12 weeks
Secondary Change in sex hormone binding globulin (SHBG) levels Assessed by plasma sex hormone binding globulin (SHBG) 6 weeks
Secondary Change in sex hormone binding globulin (SHBG) levels Assessed by plasma sex hormone binding globulin (SHBG)) 12 weeks
Secondary Change in 17-Hydroxyprogesterone (17-OHP) levels Assessed by 17-Hydroxyprogesterone (17-OHP) 6 weeks
Secondary Change in 17-Hydroxyprogesterone (17-OHP) levels Assessed by 17-Hydroxyprogesterone (17-OHP) 12 weeks
Secondary Change in appetite Measured by a validated 10-point visual analogue scale on a scale of 1-10, 1 being not hungry at all and 10 being very hungry 6 weeks
Secondary Change in appetite Measured by a validated 10-point visual analogue scale on a scale of 1-10, 1 being not hungry at all and 10 being very hungry 12 weeks
Secondary Change in markers of satiety Assess by plasma GLP-1 6 weeks
Secondary Change in markers of satiety Assess by plasma GLP-1 12 weeks
Secondary Change in markers of satiety Assess by plasma PYY 6 weeks
Secondary Change in markers of satiety Assess by plasma PYY 12 weeks
Secondary Change in markers of satiety Assess by plasma oxyntomodulin 6 weeks
Secondary Change in markers of satiety Assess by plasma oxyntomodulin 12 weeks
Secondary Change in markers of hunger Assess by plasma ghrelin 6 weeks
Secondary Change in markers of hunger Assess by plasma ghrelin 12 weeks
Secondary Change in fasting glucose Assessed in serum glucose measurements 6 weeks
Secondary Change in fasting glucose Assessed in serum glucose measurements 12 weeks
Secondary Change in HbA1c Assessed in serum HbA1c measurements 6 weeks
Secondary Change in HbA1c Assessed in serum HbA1c measurements 12 weeks
Secondary Change in lipids Assessed by Lipid profile 6 weeks
Secondary Change in lipids Assessed by Lipid profile 12 weeks
Secondary Change in lipids Assessed by Lipoprotein lipid A levels 6 weeks
Secondary Change in lipids Assessed by Lipoprotein lipid A levels 12 weeks
Secondary Change in lipids Assessed by Apolipoprotein A1 levels 6 weeks
Secondary Change in lipids Assessed by Apolipoprotein A1 levels 12 weeks
Secondary Change in lipids Assessed by Apolipoprotein B levels 6 weeks
Secondary Change in lipids Assessed by Apolipoprotein B levels 12 weeks
Secondary Change in body weight Body weight (kg) 6 weeks
Secondary Change in body weight Body weight (kg) 12 weeks
Secondary Change in body mass index BMI (kg/m2) 6 weeks
Secondary Change in body mass index BMI (kg/m2) 12 weeks
Secondary Change in anthropometric measurements (waist circumference) Waist circumference (cm) 6 weeks
Secondary Change in anthropometric measurements (waist circumference) Waist circumference (cm) 12 weeks
Secondary Change in anthropometric measurements (waist-hip ratio) Waist-hip ratio 6 weeks
Secondary Change in anthropometric measurements (waist-hip ratio) Waist-hip ratio 12 weeks
Secondary Change in dietary intake Assessed using interval dietary assessments with Nutritics 'app' 6 weeks
Secondary Change in dietary intake Assessed using interval dietary assessments with Nutritics 'app' 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT03142633 - MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Recruiting NCT05354245 - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL) N/A
Completed NCT03383822 - Regulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Suspended NCT03652987 - Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
Completed NCT04203238 - Potato Research for Enhancing Metabolic Outcomes N/A
Recruiting NCT03658564 - Preoperative Oral Carbohydrate Treatment Minimizes Insulin Resistance N/A
Completed NCT04183257 - Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics Phase 4
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT03627104 - Effect of Dietary Protein and Energy Restriction in the Improvement of Insulin Resistance in Subjects With Obesity N/A
Completed NCT05124847 - TREating Pediatric Obesity N/A
Active, not recruiting NCT03288025 - Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE) N/A
Completed NCT03809182 - Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels. Phase 4
Completed NCT01809288 - Identifying Risk for Diabetes and Heart Disease in Women
Completed NCT04642482 - Synbiotic Therapy on Intestinal Microbiota and Insulin Resistance in Obesity Phase 4
Terminated NCT03278236 - Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men? N/A
Not yet recruiting NCT06159543 - The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes N/A
Not yet recruiting NCT05540249 - Pre-operative Carbohydrates in Diabetic Patients Undergoing CABG N/A
Withdrawn NCT04741204 - Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer Phase 4